Q2 EPS Estimates for Viridian Therapeutics Raised by Wedbush
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – Equities researchers at Wedbush increased their Q2 2025 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.82) per share for the quarter, up from their previous forecast of ($1.04). The […]
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – Equities researchers at Wedbush increased their Q2 2025 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.82) per share for the quarter, up from their previous forecast of ($1.04). The […]
